about
sameAs
Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal StudiesProdromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons LearnedEquating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's diseasePrecompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's DiseaseDissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21.Diagnosis and management of dementia with Lewy bodies: third report of the DLB ConsortiumHuntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.Replication of association between ELAVL4 and Parkinson disease: the GenePD study.Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD StudyThe Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.The basal ganglia in perceptual timing: timing performance in Multiple System Atrophy and Huntington's disease.Subthalamic deep brain stimulation in Parkinson׳s disease has no significant effect on perceptual timing in the hundreds of milliseconds rangeSmartphone- and internet-assisted self-management and adherence tools to manage Parkinson's disease (SMART-PD): study protocol for a randomised controlled trial (v7; 15 August 2014).Tracking Parkinson's: Study Design and Baseline Patient Data.Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia.Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.No evidence of substantia nigra telomere shortening in Parkinson's diseaseSingle-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene.Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseLongitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease.Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.Hyperthyroid chorea.Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trialDifferential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET dataMild cognitive impairment in Parkinson disease: a multicenter pooled analysis.Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD studyGenetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome.Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of lifeNeuropsychiatric complications of medical and surgical therapies for Parkinson's disease.Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson's diseaseEffects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.Cognition in movement disorders: where can we hope to be in ten years?Longitudinal change in 99mTcHMPAO cerebral perfusion SPECT in Parkinson's disease over one yearPopulation based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)The role of levodopa in the management of dementia with Lewy bodies.
P50
Q24658443-90D6656D-0936-4B78-B9FC-C6B8BED1229FQ26738357-A41301F6-742A-4BAA-9A50-5B884EEFEFEFQ28586595-1198B364-5A17-42A3-BFDF-17955668607CQ28601965-D0E53C51-FE53-4112-AA94-5844388EDFD9Q29417095-CBF7B2A1-D2B4-493F-B404-EC2DCE01C092Q29614409-B65A963C-61E8-4745-8ADD-BF5224391D10Q30438950-81DC996C-DFCF-4BFF-827D-F4367F31A8B8Q30439050-7A8FC0F9-DE7E-4BA7-87FA-64FD56D06A46Q30439341-3E8E20B4-3E6A-494E-8F5B-23DF609F899AQ30440660-AF63C62A-51CD-45BF-ADC6-C113B7893560Q30443884-FD68B0F1-D47D-49BA-986A-B3A117544EF8Q30578248-1C1FA0FD-C2B0-47BB-8E7B-0FAEDDD8033BQ30612675-8798B96F-7BB3-4358-A7CB-6A5A3059BB98Q31008758-881031C7-234A-48E7-8F3C-F0EAE2CB83CDQ31080551-0197AE77-3CAB-4187-B86F-D05A4B55DEC3Q33193431-D00B38C4-B338-4C4A-A5E2-8D503E60477EQ33267768-1CFD8835-8F96-42FB-A466-B9462575B507Q33574058-0AD3709E-AB2F-438E-88F3-057C4BAFE8B6Q33665078-F164312F-5C0A-4A35-B36A-2040E97E7DE4Q33666819-A6F2C1E0-F7C1-4DC1-9F83-2BC7AAB2E9CDQ33698810-5F9F7D80-919C-4F55-8901-D1474A653A57Q33698810-BBAAC0E9-25B2-464D-8FB5-5177F27F15D8Q33754677-41EB3713-28CC-46B9-9F2C-63E8EA15D8C4Q33761048-63B54CCC-9E7D-439D-8C6C-991467BA6720Q33825044-C332D03F-D652-4790-8C75-F4FC78456AA3Q33869820-7168FC7B-EE94-4ED3-9C7B-CD6A1CB5CE22Q34026537-48233664-36C0-4C65-AACF-F2005C7610A0Q34031302-968E05BF-3C7E-49C2-89C3-20D363D93B20Q34060625-78C23631-AA98-4360-8B1F-544E67B6819DQ34140404-2BAFC03B-2F25-4F1E-A240-FCA178A0FF0FQ34174901-AE27B82F-F984-430E-802F-1A31DB089732Q34234597-E74AF57E-CA5F-488A-A9D8-7105A159338CQ34245237-F58FDAD4-858F-4173-8911-F8C1BB1F0190Q34325640-7D32B93D-AAF3-4706-A578-3FB680C00E1DQ34341299-E02B3EB8-D51F-4574-A30D-E3F13D913179Q34382051-9399EBBB-C777-489D-8AB5-548E340423A4Q34564670-C24AE5D2-FE7E-44AC-8796-996FC256E242Q35211553-EE02F398-672C-4A2F-8D70-5621289F18FAQ35484063-963E7793-7CD9-4002-B957-60E34B4CB572Q35487303-4498FFFD-C0BA-43FC-AA26-15F41729ADD9
P50
description
hulumtues
@sq
neuroloog
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
David Burn
@en
David Burn
@es
David Burn
@nl
David Burn
@sl
David J. Burn
@de
type
label
David Burn
@en
David Burn
@es
David Burn
@nl
David Burn
@sl
David J. Burn
@de
altLabel
Burn DJ
@en
D Burn
@en
D J Burn
@en
David J Burn
@en
David J. Burn
@en
David J. Burn
@nl
prefLabel
David Burn
@en
David Burn
@es
David Burn
@nl
David Burn
@sl
David J. Burn
@de
P214
P227
P1153
26034521700
P21
P214
P227
1044245212
P31
P4012
P496
0000-0001-7658-1209
P735
P7859
viaf-305350933